The Flinders University of South Australia

Medvet Science Pty Ltd

Heddy Zola

Ian Cameron Nicholson

Michael Alexander Thiel

Doreen Krumbiegel

Simon Barry

Douglas John Coster

Nicola Ga-Ling Eastaff-Leung

Keryn Anne Williams

The present disclosure provides an isolated protein comprising at least one antibody variable region that is capable of binding to peptidase inhibitor 16 (PI16), wherein the protein is also capable of competitively inhibiting binding of an antibody produced by a hybridoma designated CRCBT-02-001 deposited with the ATCC under Accession Number PTA-10685 to PI16. The present invention also provides use of the protein, e.g., in diagnosis, therapy or to isolate cells, preferably Treg cells.

Proteins that bind PI16 and uses thereof

A method of treating an ocular disorder is disclosed, comprising administering to a patient in need of such treatment, an effective amount of a sub-immunoglobulin antigen-binding molecule that is immuno-interactive with a target antigen associated with the disorder. The invention is also directed to compositions comprising this sub-immunoglobulin antigen-binding molecule and to a method of diagnosing an ocular condition using such molecule.

Agents and methods for treatment and diagnosis of ocular disorders

Growing community of inventors

Evandale, Australia

Heddy Zola